{"id":"W2741245320","doi":"10.1158/1538-7445.am2017-ct075","title":"Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Placebo; Hazard ratio; Oncology; Gastroenterology; Cancer; Immunotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006752751,0.0003423566,0.0008690629,0.0002611901,0.0002858157,0.0000894135,0.0004213508,0.0001573318,0.0003572234],"category_scores_gemma":[0.0001327203,0.0002366176,0.0001272339,0.0002544485,0.0005788938,0.0003103579,0.00007579215,0.0004300475,0.000007878902],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009664787,"about_ca_system_score_gemma":0.001139909,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03092435,"about_ca_topic_score_gemma":0.01116189,"domain_scores_codex":[0.9965553,0.0001492805,0.0006478881,0.0007314322,0.001193312,0.0007228155],"domain_scores_gemma":[0.9972251,0.0002735664,0.0004482998,0.001363321,0.000471817,0.0002179169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9339116,0.002867779,0.01072082,0.00006435689,0.0006115,0.0001207867,0.0009262346,0.00000762927,0.01072129,0.000006357877,0.0002290227,0.03981267],"study_design_scores_gemma":[0.7277348,0.01908576,0.2400923,0.0009072899,0.00007210392,9.853159e-7,0.0002304047,0.0000283034,0.01027048,0.00002360068,0.001272017,0.0002820067],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992608,0.0002885841,0.000001576341,0.0005319189,0.0002697125,0.002742718,0.0009340172,0.000029533,0.002594003],"genre_scores_gemma":[0.9973155,0.0007217936,0.00007316449,0.00002100841,0.0001495779,0.0003239209,0.0003420864,0.00006305497,0.0009898735],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2293714,"threshold_uncertainty_score":0.9755288,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06454676551010405,"score_gpt":0.3935429647153974,"score_spread":0.3289961992052933,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}